We are experiencing increased use of LR as maintenance fluids. How are institutions handling Y-site administration of ceftriaxone with LR? Trissel’s does show one study compatible for 4 hours with ceftriaxone 100 mg/ml y-site administration with LR, but all other studies incompatible.
Do you allow Y-site administration of ceftriaxone with LR?
Do you recommend a flush before and after to mitigate potential precipitation?
If so, what volume is sufficient to flush for compatibility concerns?

We are reviewing our sterile compounding policies and are curious how other hospitals are handling fake eyelashes.

Do you specifically identify and prohibit the use of fake eyelashes in your Sterile Compounding Policies?

If no, do you consider fake eyelashes a "cosmetic" and require that they are removed prior to entering sterile compounding area?

Hello there!

(diving into our Ambulatory BCMA journey here...)

Do you currently wristband patients in your Ambulatory clinics?
If yes, do you wristband all patients or certain subsets of patients? (which subsets of patients / how do you determine if patient needs a wristband?)

Thanks in advance!
Emily

In reviewing some data on IV contrast I am finding that there is no cross-reactivity for these agents in patients with shellfish or iodine allergies, despite a common belief that there is.

From the 2022 American College of Radiology Manual on Contrast Media:

Hello,

Do you have any policy/procedures at your institution requiring an RN to complete an in person handoff with heparin infusions (current rate, last ptt, last titration, etc) when the patient transfers, much like a controlled substance chain of custody handoff.

Your responses are appreciated,
Mara

Our nephrology team is encouraging a shift towards Cystatin C-based eGFR for drug dosing. One of our concerns is around practicing "off-label" since most FDA approved dosing is based on CrCl cut-offs. Has this been evaluated at your institution? Please select the options that match your practice, and feel free to expand upon your response in comments:

1) Serum cystatin C (Scys)-based eGFR is used for renal drug adjustment in place of Serum Creatinine (SCr)-based eGFR

Updating our stop date policy. We do NOT consider propofol a controlled substance, nor do we impose a stop date. Do any of your organizations impose a stop date if you don't consider propofol a controlled substance?

For those with CRP programs and helped build it, such as CANDOR or IHI's PACT Program, how do you recommend bringing this forward to your system leadership? How did you implement or build the case? What were the greatest hurdles needed to overcome or something you wish could have been done differently?

In other words, I'm looking for advice on how to get started, and for experience that we can model ourselves after.

Feel free to message me if needed.

We are transitioning to EPIC this fall and one of the work flows that has been suggested is that pharmacists will be responsible to release the orders for certain patients such as cath lab and surgery etc.
I am reaching out to see if any facilities follow a similar process. My limited experience with EPIC and releasing orders usually involved the physician or the nurse.
Any input is greatly appreciated

Do you use the Micromedex formulary platform for maintaining your hospital/health system formulary? We are planning on implementing this product and would like to learn more about how drugs are noted in the formulary that have restrictions or other unique notations. We understand that the Micromedex Formulary feature allows for custom 'tiers' and would love to know what 'tiers' others have developed or any other words of wisdom for effectively implementing this product.